$KPRX

Kiora Pharmaceuticals announced the publication of its Phase 1 ABACUS-1 study results for KIO-301 in Nature Medicine, confirming the drug's safety and feasibility in late-stage retinitis pigmentosa patients. KIO-301, a molecular photoswitch, aims to restore light responsiveness regardless of genetic mutation. Building on these positive findings, the company has initiated a randomized, controlled Phase 2 clinical trial (ABACUS-2) to further evaluate higher doses and functional visual improvements.